, Volume 1, Issue 2, pp 243–254

Neuroimaging in Parkinson’s disease


DOI: 10.1602/neurorx.1.2.243

Cite this article as:
Brooks, D.J. Neurotherapeutics (2004) 1: 243. doi:10.1602/neurorx.1.2.243


In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson’s disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD.

Key Words

Positron emission tomography SPECT Parkinson’s disease dopamine neuroprotection progression 
Download to read the full article text

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc 2004

Authors and Affiliations

  1. 1.Medical Research Council Clinical Sciences Center and Division of Neuroscience, Faculty of Medicine, Imperial CollegeHammersmith HospitalLondonUK

Personalised recommendations